Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | USP8 | P40818 | 2/20 | 0.33 |
| ▸ | USP7 | Q93009 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21811571 | 0.84 | KDM4E (0.37) | KDM4EALDH1A1POLBLMNACYP2C9 | |
| SCHEMBL11167087 | 0.80 | ALDH1A1 (0.46) | KDM4EALDH1A1POLBLMNASMN1; SMN2 | |
| SCHEMBL12099239 | 0.80 | ALDH1A1 (0.41) | KDM4EALDH1A1POLBCYP2C9L3MBTL1 | |
| SCHEMBL2298550 | 0.78 | EGLN2 (0.40) | KDM4EALDH1A1POLBCYP11B2 | |
| SCHEMBL125638 | 0.78 | PIK3CD (0.51) | KDM4EALDH1A1POLBLMNATSHR | |
| SCHEMBL11155546 | 0.78 | KDM4E (0.40) | KDM4EALDH1A1POLBMAPK1L3MBTL1 | |
| SCHEMBL4586295 | 0.78 | KDM4E (0.40) | KDM4EALDH1A1POLBMAPK1L3MBTL1 | |
| SCHEMBL1973193 | 0.78 | ALDH1A1 (0.40) | KDM4EALDH1A1POLBTSHRPLAU | |
| SCHEMBL12838156 | 0.78 | KDM4E (0.40) | KDM4EALDH1A1POLBPLAUMAPK1 | |
| SCHEMBL3358212 | 0.78 | PLAU (0.42) | KDM4EALDH1A1POLBPLAUMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 464 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025093624-A1 | A PROCESS FOR PREPARING 3,5-DIFLUORO-2-PYRIDINECARBOXAMIDE | INTERVET INTERNATIONAL B.V. (NL) | 2025-05-08 | — | — | WO | claimed |
| WO-2025093631-A1 | A PROCESS FOR PREPARING 2-AMINO-3,5-DIFLUOROPYRIDINE OR A SALT THEREOF | INTERVET INTERNATIONAL B.V. (NL) | 2025-05-08 | — | — | WO | claimed |
| US-20230002323-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-01-05 | — | — | US | claimed |
| US-11426393-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2022-08-30 | — | — | US | claimed |
| EP-4026829-A1 | PROCESS FOR PREPARING N-[[5-(3-CHLOROPHENYL)-3-HYDROXY-2-PYRIDINYL]CARBONYL]-GLYCINE FROM 5-(3-CHLOROPHENYL)-3-HYDROXY-2-PYRIDINE CARBOXYLIC ACID | Akebia Therapeutics Inc. (US) | 2022-07-13 | — | — | EP | claimed |
| US-11267785-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides | AKEBIA THERAPEUTICS, INC. (US) | 2022-03-08 | — | — | US | claimed |
| EP-3683209-B1 | PROCESS FOR PREPARING [(5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL)-AMINO]ACETIC ACID FROM 5-((3-CHLOROPHENYL)-3-CHLORO-PYRIDIN-2-YL)-NITRILE, AND PROCESS FOR PREPARING 5-((HALOPHENYL)-3-HALO-PYRIDIN-2-YL)-NITRILE DERIVATIVES | AKEBIA THERAPEUTICS INC (US) | 2021-11-10 | — | — | EP | claimed |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2021-05-13 | — | — | US | claimed |
| US-20210122715-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | KREOS CAPITAL VII (UK) LIMITED (GB) | 2021-04-29 | — | — | US | claimed |
| US-10738010-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | AKEBIA THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | claimed |
| EP-3683209-A1 | PROCESS FOR PREPARING [(5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL)-AMINO]ACETIC ACID FROM 5-((3-CHLOROPHENYL)-3-CHLORO-PYRIDIN-2-YL)-NITRILE, AND PROCESS FOR PREPARING 5-((HALOPHENYL)-3-HALO-PYRIDIN-2-YL)-NITRILE DERIVATIVES | Akebia Therapeutics Inc. (US) | 2020-07-22 | — | — | EP | claimed |
| CN-110498767-A | The synthetic method of the chloro- 2- cyanopyridine of 3,5- bis- | CHONGQING MEDICAL & PHARMACEUTICAL COLLEGE | 2019-11-26 | — | — | CN | claimed |
| CN-109020882-A | The synthetic method of the chloro- 2- cyanopyridine of 3,5- bis- | 杭州华东医药集团浙江华义制药有限公司 | 2018-12-18 | — | — | CN | claimed |
| US-12624006-B2 | Process for the preparation of 5-(1-cyanocyclopropyl)-pyridine-2-carboxylic acid esters amides and nitriles | SYNGENTA CROP PROTECTION AG (CH) | 2026-05-12 | — | — | US | disclosed |
| US-12612367-B2 | Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative | AKEBIA THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4705294-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS CCR4 MODULATORS | Aurigene Oncology Limited (IN) | 2026-03-11 | — | — | EP | disclosed |
| US-5716971-A | FOR TREATMENT OF ANGINA PECTORIS AND HYPERTENSION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0623597-B1 | Pyridine derivatives, with potassium channel opening activity | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-10-22 | — | — | EP | disclosed |
| EP-0623597-A1 | Pyridine derivatives, with potassium channel opening activity | Takeda Chemical Industries, Ltd. (JP) | 1994-11-09 | — | — | EP | disclosed |
| US-4371537-A | Sulfur-substituted phenoxypyridines having antiviral activity | THE DOW CHEMICAL COMPANY (US) | 1983-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11426393-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | KDM4E 562/4885ALDH1A1 444/4885POLB 480/4885 |
| US-10738010-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | HPD, APEH, P4HA1 | KDM4E 779/4885ALDH1A1 28/4885POLB 1709/4885 |
| US-20210122715-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | HPD, APEH, P4HA1 | KDM4E 779/4885ALDH1A1 28/4885POLB 1709/4885 |
| US-11267785-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides | HPD, APEH, P4HA1 | KDM4E 779/4885ALDH1A1 28/4885POLB 1709/4885 |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | KDM4E 562/4885ALDH1A1 444/4885POLB 480/4885 |
| US-12612367-B2 | Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative | DIMT1, HIF1A, HIF1AN | KDM4E 1446/4885ALDH1A1 64/4885POLB 2047/4885 |
| US-12624006-B2 | Process for the preparation of 5-(1-cyanocyclopropyl)-pyridine-2-carboxylic acid esters amides and nitriles | SCN9A, CLIC4, SCN1B | KDM4E 495/4885ALDH1A1 1437/4885POLB 3534/4885 |
| US-20230002323-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | HPD, APEH, P4HA1 | KDM4E 779/4885ALDH1A1 28/4885POLB 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.